Bioactivity | Perindoprilat-d3 disodium is deuterated labeled Perindoprilat (HY-B1433). Perindoprilat (S 9780) is an angiotensin-converting enzyme (ACE) inhibitor with the IC50 value ranging from 1.5 to 3.2 nM. Perindoprilat can be used in hypertension research[1][2]. |
Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中,主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注,因为它可能影响药物的药代动力学和代谢谱[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Perindoprilat-d3 disodium 相关抗体: |
In Vivo | Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment improves cardiac function in mice with acute myocardial infarction and reduces the number of apoptotic myocardial cells[5].Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment reduces the expression levels of myocardial Bax and Bcl-2 in infarction zones of mice with acute myocardial infarction[5].Perindoprilat (oral gavage; 1.5 mg/kg; once daily; 7 d) treatment lowers the expression of myocardial TLR4/NF-κB in infarction zones in mice with acute myocardial infarction[5]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
Formula | C17H23D3N2Na2O5 |
Molar Mass | 387.40 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Izabella Z A Pawluczyk, et al. The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells. Kidney Int. 2004 Apr;65(4):1240-51. [3]. Perindopril. Expert Opin Pharmacother. 2006 Jan;7(1):63-71. [4]. X-Z Wang, et al. Perindopril inhibits myocardial apoptosis in mice with acute myocardial infarction through TLR4/NF-κB pathway. Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6672-6682. [5]. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6. |